Biotechnology and Diagnostics — Impairment Charges
Danaher Biotechnology and Diagnostics — Impairment Charges increased by 424.7% to $101.00M in Q3 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase in impairment charges suggests a deterioration in the expected performance or market value of the segment's assets, potentially signaling poor past acquisition performance or adverse industry trends. A decrease or absence of charges indicates that asset valuations remain supported by current and projected business performance.
Detailed definition
This metric represents the non-cash expense recognized when the carrying value of long-lived assets, such as goodwill, i...
Peer comparison
Peers in the life sciences and diagnostics industry typically report these charges periodically following annual impairment testing or triggered events, with high-growth companies often showing higher volatility due to frequent M&A activity.
dhr_segment_biotechnology_and_diagnostics_segment_impairment_chargesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '25 | |
|---|---|---|---|---|---|
| Value | $19.25M | $19.25M | $19.25M | $19.25M | $101.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +424.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology and diagnostics — impairment charges?
- Danaher (DHR) reported biotechnology and diagnostics — impairment charges of $101.00M in Q3 2025.
- What does biotechnology and diagnostics — impairment charges mean?
- The amount of value written off from assets within the Biotechnology and Diagnostics segment because they are no longer worth as much as previously recorded on the balance sheet.